Channing Der, PhD

Dr. Chenning Der's pioneering research on RAS oncogenes in human cancer has made significant contributions to the study of RAS and RAS-related oncoproteins in cancer. His work has been funded by the National Cancer Institute, Department of Defense, Lustgarten Foundation, and Pancreatic Cancer Action Network. He has authored over 350 publications and holds seven patents. Dr. Der has also mentored more than 50 post-doctoral and 30 pre-doctoral fellows.

He is a member of the NCI RAS Working Group and the scientific advisory boards of the Pancreatic Cancer Action Network and biotech companies developing anti-RAS therapeutics. He previously served on the NCI Board of Scientific Counselors, the Frederick National Laboratory Advisory Committee, and the scientific advisory board of the Lustgarten Foundation.

Dr. Der's accolades include being a Fellow of the AAAS, receiving the NCI Outstanding Investigator Award, the Battle Distinguished Cancer Research Award, the Mentorship Award for Lifetime Achievement, the University of California, Irvine Distinguished Alumnus Award, and the Einstein BIH Visiting Fellow Award. He has served on numerous editorial boards and consulted for many pharmaceutical and biotech companies.

Dr. Der earned his PhD from the University of California, Irvine, and completed his postdoctoral studies at Harvard Medical School/Dana-Farber Cancer Institute.